1. Pink Sheet

Sharpless Wonders Why Cancer Success Doesn't Translate To Other Diseases

 
• By Derrick Gingery

Acting US FDA commissioner also said he wants to be nominated to the permanent position.

FDA acting Commissioner Ned Sharpless at Reagan-Udall Foundation for FDA. (1)
Acting FDA Commissioner Norman Sharpless wants the success in cancer drug development disseminated to other disease areas. • Source: File photo

Acting US Food and Drug Administration Commissioner Norman Sharpless wants the oncology community to share the secret of its regulatory success.

During an event on cancer care and policy, Sharpless wondered whether additional tools are necessary to translate the level of development success in cancer to other disease areas like

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.